The Covid-19 pandemic weighed down sales for some Pfizer Inc. drugs in the latest quarter as the company’s candidate vaccine for the virus that has caused the public-health crisis continues in a large late-stage trial.
The New York City-based company recorded third-quarter sales of $12.13 billion, compared with $12.68 billion in the same three-month period last year. Analysts surveyed by FactSet had forecast $12.31 billion of sales
The…
This post first appeared on wsj.com
